Neuroinflammation Across Ad, Pd, And Als plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Neuroinflammation is a hallmark feature shared across Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). While each disease has distinct clinical and pathological features, chronic activation of the innate immune system in the brain—primarily driven by microglia and astrocytes—contributes to neuronal dysfunction and death in all three conditions. This integration page synthesizes the common and disease-specific inflammatory pathways that link these major neurodegenerative disorders[@griciuc2018].
The inflammatory response in neurodegeneration is characterized by elevated pro-inflammatory cytokines, reactive oxygen species (ROS) production, [complement system](/entities/complement-system) activation, and persistent activation of pattern recognition receptors such as TLRs and NLRs. Understanding these shared inflammatory mechanisms provides opportunities for therapeutic interventions that may benefit multiple neurodegenerative conditions[@griciuc2013].
Neuroinflammation Across Ad, Pd, And Als plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Neuroinflammation is a hallmark feature shared across Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). While each disease has distinct clinical and pathological features, chronic activation of the innate immune system in the brain—primarily driven by microglia and astrocytes—contributes to neuronal dysfunction and death in all three conditions. This integration page synthesizes the common and disease-specific inflammatory pathways that link these major neurodegenerative disorders[@griciuc2018].
The inflammatory response in neurodegeneration is characterized by elevated pro-inflammatory cytokines, reactive oxygen species (ROS) production, [complement system](/entities/complement-system) activation, and persistent activation of pattern recognition receptors such as TLRs and NLRs. Understanding these shared inflammatory mechanisms provides opportunities for therapeutic interventions that may benefit multiple neurodegenerative conditions[@griciuc2013].
[Microglia](/cell-types/microglia-neuroinflammation) are the resident immune cells of the central nervous system and serve as the first line of defense against pathogens and cellular debris. In neurodegenerative diseases, chronic microglial activation—often termed "microglial priming"—creates a self-perpetuating cycle of inflammation[@heneka2017]. [@liddelow2017]
Key microglial pathways activated in neurodegeneration include: [@swanson2019]
[Astrocytes](/entities/astrocytes) adopt reactive phenotypes in response to neuroinflammation, transitioning from their homeostatic functions to inflammatory states. Reactive astrocytes produce cytokines, chemokines, and complement proteins that can both protect and harm [neurons](/entities/neurons)[@liddelow2017].
In AD, reactive astrocytes cluster around amyloid plaques and may both limit plaque spread and contribute to neuronal dysfunction. In PD, astrocyte reactivity surrounds dopaminergic neurons in the substantia nigra, and astrocytic dysfunction may contribute to [alpha-synuclein](/proteins/alpha-synuclein) propagation. In ALS, astrocytes fail to support motor neurons and release toxic inflammatory mediators.
The [NLRP3](/entities/nlrp3-inflammasome) (NLR family pyrin domain containing 3) inflammasome is a cytosolic protein complex that activates caspase-1, leading to maturation and release of pro-inflammatory cytokines IL-1β and IL-18. The NLRP3 inflammasome is activated by various neurodegeneration-associated signals including amyloid-beta fibrils, alpha-synuclein oligomers, and mitochondrial [ROS](/entities/reactive-oxygen-species)[@swanson2019].
In AD, neuroinflammation is driven primarily by amyloid-beta plaques and [tau](/proteins/tau) pathology. Microglial cells surround plaques in an attempt to clear amyloid, but chronic activation leads to a pro-inflammatory state that exacerbates tau pathology and synaptic loss.
Key inflammatory mechanisms in AD include:
In PD, neuroinflammation accompanies alpha-synuclein aggregation and dopaminergic neuron loss. The inflammatory response may be both a cause and consequence of alpha-synuclein pathology.
Key inflammatory mechanisms in PD include:
ALS features neuroinflammation driven by mutant SOD1, [TDP-43](/mechanisms/tdp-43-proteinopathy), and FUS protein aggregates. Both microglia and astrocytes contribute to motor neuron injury.
Key inflammatory mechanisms in ALS include:
Several anti-inflammatory approaches are being explored across AD, PD, and ALS:
Beyond direct anti-inflammatory strategies, immunomodulatory approaches include:
| Mechanism | AD | PD | ALS |
|-----------|----|----|-----|
| Microglial activation | +++ | +++ | +++ |
| NLRP3 inflammasome | +++ | +++ | +++ |
| Complement activation | +++ | ++ | +++ |
| Astrocyte reactivity | +++ | +++ | +++ |
| TREM2 involvement | +++ | ++ | + |
| Peripheral immune cell infiltration | + | +++ | +++ |
Legend: +++ = major contributor, ++ = significant, + = moderate
The innate immune system recognizes pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) through pattern recognition receptors (PRRs). In neurodegeneration, key PRR families include:
Toll-like receptors (TLRs)
[TLR4](/entities/tlr4) recognizes amyloid-beta and alpha-synuclein, triggering MyD88-dependent pro-inflammatory signaling. TLR2 detects damaged myelin and cellular debris. TLR signaling induces NF-κB activation and cytokine production, creating a chronic inflammatory environment that exacerbates neuronal dysfunction.
NOD-like receptors (NLRs)
The [NLRP3](/entities/nlrp3-inflammasome) inflammasome is a cytosolic multiprotein complex that activates caspase-1, leading to maturation of pro-inflammatory cytokines IL-1β and IL-18. In neurodegenerative diseases, NLRP3 is activated by:
Pro-inflammatory cytokines
The complement system plays a dual role in neurodegeneration—providing protection through debris clearance while contributing to synaptic loss and inflammation when overactivated.
Complement activation in AD
Amyloid-beta directly activates the classical complement pathway through C1q binding. This leads to opsonization of synapses and neurons, marking them for phagocytic removal. C1q and C3 are found associated with amyloid plaques, and complement activation correlates with synaptic loss in AD brains.
Complement in PD
Alpha-synuclein activates complement, and complement components are detected in Lewy bodies. The membrane attack complex (MAC) may directly damage dopaminergic neurons. Genetic variants in complement genes influence PD risk.
Complement in ALS
C1q and C3 are upregulated in ALS spinal cord, and complement activation contributes to motor neuron injury. Astrocyte-derived complement may be particularly important in ALS pathogenesis.
Chemokines direct immune cell migration and influence neuroinflammation:
Microglia adopt diverse activation states in neurodegeneration, moving beyond the classical M1/M2 dichotomy:
Disease-associated microglia (DAM)
In AD, a distinct population of disease-associated microglia emerges, characterized by upregulation of genes involved in lipid metabolism, phagocytosis, and lysosomal function. DAM formation requires TREM2 signaling and represents an attempt at protective response that becomes dysregulated.
Neurotoxic microglial phenotype
Pro-inflammatory microglia produce ROS, nitrogen species, and cytokines that damage neurons. This phenotype is induced by:
Alternatively activated microglia can support neuronal survival through:
Astrocytes display remarkable heterogeneity in neurodegenerative diseases:
A1 reactive astrocytes
As described by Liddelow et al., A1 astrocytes are induced by microglial release of IL-1α, TNF, and C1q. These astrocytes lose supportive functions and gain neurotoxic properties, releasing complement components that eliminate synapses.
A2 reactive astrocytes
A2 astrocytes are considered neuroprotective, upregulating genes involved in tissue repair, glycogen metabolism, and neurotrophic support. The balance between A1 and A2 phenotypes may influence disease progression.
Astrocyte contributions by disease
In AD, reactive astrocytes surround amyloid plaques and may both limit plaque growth and contribute to neuronal dysfunction through release of inflammatory mediators. In PD, astrocytes accumulate alpha-synuclein and may serve as vectors for pathological protein spread. In ALS, astrocytes fail to support motor neurons and release toxic inflammatory mediators.
T cells in neurodegeneration
CD4+ and CD8+ T cells infiltrate the brain in AD, PD, and ALS. Regulatory T cells (Tregs) may provide neuroprotective effects, while effector T cells contribute to inflammation. T cell phenotypes differ across diseases:
B cells and autoantibodies are implicated in neurodegeneration:
BBB dysfunction contributes to neuroinflammation by allowing peripheral immune cell entry:
BBB breakdown in AD
BBB disruption occurs early in AD, with regional variations corresponding to atrophy patterns. Pericyte loss and endothelial dysfunction contribute to leakage of plasma proteins and immune cells.
BBB in PD
Dopaminergic neurons are adjacent to blood vessels in the substantia nigra, making them vulnerable to circulating toxins and inflammatory mediators. BBB breakdown has been documented in PD animal models and patients.
ALS and the BBB
Vascular leakiness in ALS spinal cord allows immune cell infiltration. The extent of BBB disruption correlates with disease severity.
CSF1R antagonists
Colony stimulating factor 1 receptor (CSF1R) is required for microglial survival. CSF1R antagonists (e.g., pexidartinib) can reduce microglial numbers in the brain, and this approach is being explored in AD and ALS models.
TREM2 modulators
TREM2 agonists could enhance protective microglial responses in AD. Monoclonal antibodies against TREM2 are in development to enhance signaling while avoiding the complications of full agonism.
CD33 inhibitors
CD33 is an inhibitory receptor that reduces microglial phagocytosis. CD33 genetic variants that reduce expression are associated with lower AD risk, suggesting CD33 inhibition could be therapeutic.
Small molecule inhibitors
MCC950 is a potent NLRP3 inhibitor that has shown efficacy in preclinical models of AD, PD, and ALS. It blocks inflammasome activation and reduces IL-1β production. Other NLRP3 inhibitors in development include dapansutrile (OLT1177) and β-sitosterol.
Natural compounds
Several natural compounds inhibit NLRP3:
Minocycline
This tetracycline antibiotic has anti-inflammatory properties and has been trialed in AD, PD, and ALS. Results have been mixed, possibly due to timing of intervention and patient selection.
NSAIDs
Epidemiological studies suggest reduced AD risk with long-term NSAID use, but clinical trials have not confirmed benefit. The failure may relate to disease stage, NSAID class, and trial design.
Corticosteroids
Brief courses of corticosteroids may provide temporary benefit in ALS, but chronic use causes unacceptable side effects.
Vaccination approaches
Active immunization against amyloid-beta, tau, and alpha-synuclein is in development. Challenges include:
Cytokine blockade
Targeting specific cytokines:
Rather than pure immunosuppression, approaches that restore immune homeostasis are being explored:
Microglial repopulation
After CSF1R antagonist treatment, microglia can repopulate the brain with a potentially less inflammatory phenotype.
Regulatory immune cell enhancement
Boosting Tregs or regulatory B cells could restore immune balance without broad immunosuppression.
Metabolic modulation
Microglial metabolic state influences their inflammatory phenotype. Targeting glycolysis or oxidative phosphorylation pathways may shift microglial polarization.
Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.
However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.
The study of Neuroinflammation Across Ad, Pd, And Als has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.